Company profilePharmaceutical#640 of 1,318 in Pakistan✓ No DRAP alerts

PHARMAKO PAKISTAN

Pharmaceutical company · 17 brands · 17 molecules

17 registered products 39 pharmaceutical brands 17 distinct molecules 0 DRAP alerts

Company overview

17
registered products
39
pharmaceutical brands
17
distinct molecules
0
therapeutic classes
0
DRAP alerts

PHARMAKO PAKISTAN is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 17 product registrations across 17 distinct molecules. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by PHARMAKO

1 product matched in our catalogue — each with its observed price and DRAP approved ceiling.

Top molecules by brand count

Tocopherol13 brands
Retinol6 brands
Calcitriol4 brands
D-Pantothenol2 brands
Hydroquinone2 brands
Kaolin1 brand

Price band (DRAP official ceilings)

Registered products priced by source
DVAGO1 products · Rs 2,422.5 – Rs 2,422.5
Median across source: Rs 2,422.5

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Wilshire Laboratories (Private) Limited holds 133 molecules not in this portfolio
AcyclovirAcyclovir SodiumAlfacalcidolAmlodipineAmoxicillinAmoxycillin
ABBOTT LABORATORIES (PAKISTAN) LIMITED. holds 113 molecules not in this portfolio
AcetylcysteineAcriflavineAcyclovirAcyclovir Inf/OralAlcoholAluminium Hydroxide
Pfizer Laboratories (Pvt) Ltd. holds 131 molecules not in this portfolio
AlprazolamAluminium HydroxideAluminium Hydroxide And OxideAmlodipineAmodiaquineAmodiaquine Base

Get the full profile for PHARMAKO

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.